Clinical trial
Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii…
NCT00300404 · Zentrum für Integrative Psychiatrie, Other · Completed
Key facts
| NCT number | NCT00300404 |
|---|---|
| Title | Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression |
| Official title | Effect of Add-on Anti-Toxoplasmosis Treatment on Parameters Defining Toxoplasma Gondii Infection and on Psychopathology in Patients With Schizophrenia or Major Depression Serologically Positive for Toxoplasma Gondii - Phase 3 Study |
| Lead sponsor | Zentrum für Integrative Psychiatrie, Other |
| Collaborators | Stanley Medical Research Institute |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia, Major Depression |
| Intervention type | Drug |
| Interventions | daraprim, pyrimethamine, folinic acid |
| Enrollment | 40 |
| Start date | Jan 1, 2002 |
| Completion | Sep 1, 2005 |
| First posted | Mar 8, 2006 |
| Last update posted | May 22, 2006 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: